This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



quetiapine (Seroquel XL®)


Reference No. 1167

Publication date:
13/10/2011


Appraisal information

quetiapine (Seroquel XL®) prolonged-release tablet


Company: AstraZeneca UK Ltd
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 11/10/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, quetiapine prolonged release (Seroquel XL®) cannot be endorsed for use within NHS Wales for the treatment of major depressive episodes in bipolar disorder.
Statement of Advice (SOA)
Download